MentionFox
Home › Executive changes › Transcode Therapeutics, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Transcode Therapeutics, Inc. executive changes

Every leadership change Transcode Therapeutics, Inc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings1
Latest filing2026-09-11

Transcode Therapeutics, Inc. filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-11. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-09-11 · 8-K

Reported

Departure of Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director On September 10, 2026, TransCode Therapeutics, Inc. (the "Company") announced that Thomas A. Fitzgerald, M.B.A. had resigned as Chief Financial Officer, principal financial officer and principal accounting officer of the Company, and as a member of the Board of Directors of the Company (the "Board"), as well as from all other officer and director positions he held with the Company and any of its subsidiaries, in each case effective as of September 9, 2026 (the "Separation Date").
Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Transcode Therapeutics, Inc., with the record behind each one.

Find candidates like senior executive at Transcode Therapeutics, Inc.
Selling to Transcode Therapeutics, Inc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Transcode Therapeutics, Inc. is in the news or changes leadership.

Get an alert when Transcode Therapeutics, Inc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Transcode Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/transcode-therapeutics
Last updated 2026-09-27
Primary record: SEC filing
Transcode Therapeutics, Inc. (RNAZ) executive changes: 1 leadership filing. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/transcode-therapeutics